Daily Endocrinology Research Analysis
Analyzed 109 papers and selected 3 impactful papers.
Summary
Across endocrinology this cycle, a double-blind RCT shows pemafibrate extended-release safely lowers LDL-C by ~20–25% in statin-intolerant hypercholesterolemia. Pediatric MASLD was partitioned into three clinically distinct metabotypes with pathway-level differences, and an age-stratified framework for pediatric thyroid cytology recalibrates malignancy risk and likelihood ratios, addressing verification bias.
Research Themes
- Precision cardiometabolic therapeutics for statin intolerance
- Phenotype-driven stratification in pediatric MASLD
- Age-tailored diagnostic risk modeling in pediatric thyroid nodules
Selected Articles
1. Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
In a 12-week, double-blind RCT of statin-intolerant hypercholesterolemia with normal triglycerides (n=71), pemafibrate XR reduced LDL-C by 20–25% versus negligible change with placebo and lowered apolipoprotein B. Safety profiles were similar across arms with slightly higher treatment-emergent events in active groups.
Impact: This trial provides high-quality randomized evidence for a non-statin option to lower LDL-C in statin-intolerant patients, addressing a frequent clinical gap.
Clinical Implications: Pemafibrate XR can be considered to reduce LDL-C and apoB in statin-intolerant patients with normal triglycerides, though longer trials with clinical outcomes are needed before guideline changes.
Key Findings
- Pemafibrate XR 0.2 mg/d and 0.4 mg/d reduced LDL-C by −20.0% and −24.8%, respectively, versus −0.4% with placebo at 12 weeks.
- Apolipoprotein B decreased by −18.2% (0.2 mg) and −20.6% (0.4 mg) compared with placebo (P<.001).
- Treatment-emergent adverse events were similar across groups, slightly higher with pemafibrate (approximately 48–54%) versus placebo (38%).
Methodological Strengths
- Randomized, double-blind, placebo-controlled, multicenter design
- Clear primary endpoint with effect sizes and confidence intervals
Limitations
- Small sample size and 12-week duration limit assessment of clinical outcomes
- Generalizability limited to statin-intolerant patients with normal triglycerides
Future Directions: Longer, larger outcome trials should test pemafibrate’s effects on ASCVD events and assess broader dyslipidemic populations, including mixed hyperlipidemia.
BACKGROUND: Management of low-density lipoprotein cholesterol (LDL-C) in patients with statin intolerance requires treatment options beyond statins. Pemafibrate, primarily used to lower serum triglycerides in patients with hypertriglyceridemia, has also been reported in some clinical trials to reduce LDL-C. OBJECTIVE: To evaluate the efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia. METHODS: In this phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, patients with statin-intolerant hypercholesterolemia and normal triglyceride levels were enrolled. The primary endpoint was the percentage change in calculated LDL-C from baseline to week 12. RESULTS: Seventy-one patients were randomly assigned to receive placebo or the extended-release (XR) formulation of pemafibrate at 0.2 mg/d or 0.4 mg/d. LDL-C decreased significantly from baseline in the pemafibrate groups (least squares mean [95% CI]: -20.0% [-24.1 to -15.9] for XR 0.2 mg/d; -24.8% [-28.8 to -20.9] for XR 0.4 mg/d), demonstrating superiority over placebo (-0.4% [-4.2 to 3.5]). Reductions in apolipoprotein B were also greater in the pemafibrate groups than in the placebo group (least squares mean; -18.2% for XR 0.2 mg/d; -20.6% for XR 0.4 mg/d; P < .001 vs placebo). Treatment-emergent adverse events were generally similar across groups, though slightly more frequent in the pemafibrate groups (47.8% for XR 0.2 mg/d and 54.2% for XR 0.4 mg/d) than in the placebo group (37.5%). CONCLUSION: Pemafibrate effectively and safely reduces LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels, offering a potential new therapeutic option for this population.
2. Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data.
Using unsupervised clustering of clinical and metabolomics data in 514 biopsy-proven pediatric MASLD cases, three reproducible metabotypes emerged with distinct clinical and pathway signatures. Tryptophan–kynurenine metabolism associated with fibrosis in the inflammatory-fibrotic subtype, while branched-chain amino acid degradation and butanoate/purine pathways marked the cardiometabolic subtype.
Impact: This stratifies pediatric MASLD into biologically grounded subtypes, enabling mechanism-based trial design and targeted interventions rather than one-size-fits-all management.
Clinical Implications: Subtyping can guide surveillance intensity and therapeutic selection (e.g., anti-inflammatory/antifibrotic strategies for inflammatory-fibrotic; cardiometabolic risk modification for cardiometabolic subtype).
Key Findings
- Three metabotypes were identified: early-mild (49.4%), cardiometabolic (36.8%), and inflammatory-fibrotic (13.8%).
- Inflammatory-fibrotic subtype showed elevated kynurenine pathway metabolites that correlated with fibrosis stage.
- Cardiometabolic subtype enriched for branched-chain amino acid degradation, butanoate, and purine metabolism pathways.
Methodological Strengths
- Integration of biopsy-proven phenotype with metabolomics across NASH CRN studies
- Unsupervised clustering with pathway/network enrichment analyses
Limitations
- Validation in independent cohorts is required to confirm generalizability
- Observational design limits causal inference for pathway–phenotype links
Future Directions: Prospective validation and metabotype-stratified interventional trials targeting identified pathways (e.g., kynurenine metabolism) in pediatric MASLD.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide, yet treatment remains "one size fits all," despite phenotypic heterogeneity. We analyzed clinical and metabolomics data from 514 children (ages 5-18, 73% male) with biopsy-proven MASLD across three NASH Clinical Research Network studies. Unsupervised clustering of clinical data identified three distinct metabotypes: early-mild (49.4%, youngest, lowest lipids, liver enzymes, insulin resistance), cardiometabolic (36.8%, highest waist circumference, lipids, uric acid, SBP), and inflammatory-fibrotic (13.8%, highest liver enzymes, steatohepatitis, advanced fibrosis). Integrative network and pathway enrichment analyses revealed alterations in tryptophan metabolism within the inflammatory-fibrotic group, including elevated kynurenine pathway metabolites, which were significantly correlated with fibrosis stage. Branched-chain amino acid degradation, butanoate, and purine metabolism demonstrated greater enrichment in the cardiometabolic group. Here, we show that pediatric MASLD subtypes differ in clinical and metabolic features, providing a framework for targeted interventions, with validation needed in independent cohorts.
3. Age-Specific Risk of Malignancy in Pediatric Thyroid Cytology: Reframing ROM based on pre-test probability.
In 2,728 pediatric and young adult FNAs reclassified by 2023 Bethesda, age strongly influenced malignancy risk and post-test probabilities. Verification bias was quantified by contrasting lower-bound versus surgery-only upper-bound ROM, and age-stratified likelihood ratios provide individualized estimates to guide surgery, molecular testing, and follow-up.
Impact: Provides a practical, age-stratified LR framework that corrects for verification bias and recalibrates Bethesda ROM in pediatric thyroid cytology—directly informing clinical decisions.
Clinical Implications: Use age-specific LRs and post-test probabilities to tailor thresholds for surgery and molecular testing, especially in indeterminate categories; benign results with low LR can substantially downshift risk.
Key Findings
- Malignancy prevalence among operated nodules decreased with age (84.2% at 0–8 years vs 64.6% at 19–25 years).
- Verification bias was large: 24.6% malignancy under lower-bound versus 67.7% among surgical cases.
- Benign cytology yielded low LRs (0.07–0.15), reducing post-test malignancy probability to 0–25%; follicular neoplasm risk varied by age (~71% at 9 years vs ~49% at 24 years).
Methodological Strengths
- Large multicenter dataset with reclassification to 2023 Bethesda and explicit age-banding
- Quantitative approach separating lower- and upper-bound ROM to address verification bias with Bayes’ theorem
Limitations
- Retrospective design and incomplete histology for non-operated FNAs
- Potential referral and center effects across tertiary sites
Future Directions: Prospective validation of age-specific LRs with standardized follow-up and incorporation into decision-support tools; evaluation of integration with molecular testing panels.
OBJECTIVE: Paediatric thyroid nodules are uncommon but have a higher malignancy rate than adult nodules. Existing Bethesda risk-of-malignancy (ROM) estimates are not age-stratified and are affected by verification bias. We aimed to generate age-specific ROM, likelihood ratios (LRs), and post-test malignancy probabilities for paediatric and young adult thyroid cytology. METHODS: We analysed 2,728 thyroid fine-needle aspirations (FNAs) from patients aged 0-25 years across multiple tertiary centres (2000-2023). All cases were classified or reclassified using the 2023 Bethesda System and grouped into four age bands (0-8, 9-14, 15-18, and 19-25 years). We calculated lower-bound ROM (ROM overall; assuming non-operated FNAs were benign) and surgery-only upper-bound ROM (ROM surgery; 991 of 2,728 cases with histology). Age-specific pretest probabilities and Bethesda-category LRs were used to compute post-test malignancy probabilities with Bayes' theorem. RESULTS: Among operated nodules, malignancy prevalence decreased with age (84.2% at 0-8 years to 64.6% at 19-25 years). Verification bias was substantial: malignancy prevalence was 24.6% (671/2,728) under the lower-bound assumption but 67.7% (671/991) among surgical cases. Upper-bound ROM values were 2-10 times higher than lower-bound values across categories. Benign cytology showed low LRs (0.07-0.15), reducing post-test malignancy probability to 0-25%. Indeterminate categories showed age-related variation; for example, a follicular neoplasm diagnosis carried a ∼71% post-test risk in a 9-year-old versus ∼49% in a 24-year-old. AUS subtyping (nuclear vs other atypia) did not consistently separate ROM. CONCLUSIONS: Age substantially modifies both pretest and post-test malignancy probabilities in paediatric thyroid cytology. An age-stratified LR framework helps quantify verification bias and provides individualized risk estimates to guide decisions about surgery, molecular testing, and follow-up.